Risk factor
Very poor trading liquidity
Profitability factor
Very strong margins and returns
About
Jenburkt Pharmaceuticals Ltd. specializes in the creation and commercialization of a wide array of medicinal formulations and healthcare products. Its extensive product range includes treatments for parasitic infestations (anthelmintic), bone density disorders (anti-osteoporotic), joint inflammation (anti-arthritic), stomach ulcers (anti-ulcerants), and bacterial infections (antibiotics). The company also provides aphrodisiacs, remedies for coughs and colds, and dermatological solutions for allergies. Operations are structured into two main divisions: domestic sales and international exports. Jenburkt Pharmaceuticals was founded on June 10, 1985, by Hemendra N. Bhuta, Uttambhai Nandlal Bhuta, and Harshad N. Bhuta, and its corporate headquarters are located in Mumbai, India.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on